CSL Behring will close California office as part of shrinking ex vivo worknews2024-11-18T19:34:37+00:00November 18th, 2024|Endpoints News|
FDA offers more guidance on developing cell and gene therapiesnews2024-11-18T19:21:10+00:00November 18th, 2024|Endpoints News|
Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis assetnews2024-11-18T09:09:43+00:00November 18th, 2024|Endpoints News|
Gilead to close Philadelphia and Seattle offices, make job cutsnews2024-11-14T20:30:36+00:00November 14th, 2024|Endpoints News|
Arc Institute debuts AI model Evo, makes new CRISPR systemsnews2024-11-14T19:00:55+00:00November 14th, 2024|Endpoints News|
FDA approves PTC’s ultra-rare disease gene therapynews2024-11-14T05:11:24+00:00November 14th, 2024|Endpoints News|
Adaptimmune’s second T cell receptor cell therapy for rare sarcomas passes pivotal testnews2024-11-13T16:07:00+00:00November 13th, 2024|Endpoints News|
Neurogene’s stock falls in post-market trading after early data in Rett syndromenews2024-11-12T05:16:30+00:00November 12th, 2024|Endpoints News|
Aurion, Alcon enter legal battle over IPO plannews2024-11-11T11:30:23+00:00November 11th, 2024|Endpoints News|
Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancernews2024-11-11T08:09:09+00:00November 11th, 2024|Endpoints News|
